Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice

Annals of Surgical Oncology

Volumn 14, Issue 4, 2007, Pages 1374-1380

  Mita, Yoshiyasu ^a   Ajiki, Tetsuo ^a   Kamigaki, Takashi ^a   Okazaki, Taro ^a   Hori, Hiroshige ^a   Horiuchi, Hideki ^a   Hirata, Kenro ^a   Fujita, Tsunenori ^a   Fujimori, Takahiro ^b   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Gallbladder cancer; Gemcitabine; PCNA; Survival

Indexed keywords

CYCLINE; FLUOROURACIL; GEMCITABINE;

ABDOMINAL TUMOR; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILIARY TRACT CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RANDOMIZATION; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BILE DUCT NEOPLASMS; CELL PROLIFERATION; DEOXYCYTIDINE; GALLBLADDER NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34047196510     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9191-9     Document Type: Article

References (27)

1. Diehl AK. Epidemiology of gallbladder cancer: a synthesis of recent data. J Natl Cancer Inst 1980; 65:1209-14.
2. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12:1403-6.
3. Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22:193-8.
4. Eng C, Ramanathan RK, Wong MK, et al. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 2004; 27:565-9.
5. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16:279-81.
6. Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005; 104:1237-45.
7. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35:68-73.
8. Ishii H, Furuse J, Kinoshita T, et al. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn J Clin Oncol 2005; 35:526-30.
9. Matsui K, Hirashima T, Nitta T, et al. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 2005; 35:181-7.
10. Okusaka T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57:647-53.
11. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936-48.
12. Solorzano CC, Hwang R, Baker CH, et al. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003; 9:1858-67.
13. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003; 23:957-63.
14. Horiuchi H, Kawamata H, Furihata T, et al. A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice. J Exp Clin Cancer Res 2004; 23:599-606.
15. Homma S, Hasumura S, Nagamori S, Kameda H. Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell 1988; 1:95-7.
16. Habara K, Ajiki T, Kamigaki T, Nakamura T, Kuroda Y. High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. Jpn J Cancer Res 2001; 92:1127-32.
17. Knuth A, Gabbert H, Dippold W, et al. Biliary adenocarcinoma characterization of three new human tumor cell lines. J Hepatol 1988; 1:579-96.
18. Ajiki T, Kamigaki T, Hasegawa Y, et al. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepatogastroenterology 2001; 48:1266-70.
19. Kakinoki K, Fujino Y, Suzuki Y, et al. Protection against ischemia/reperfusion injury by the cavitary two-layer method in canine small intestinal transplantation with reduction of reactive oxygen species. Surgery 2004; 135:642-8.
20. Ajiki T, Hirata K, Okazaki T, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. Anticancer Res 2006; 26:1391-6.
21. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
22. Okino H, Maeyama R, Manabe T, Matsuda T, Tanaka M. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice. Clin Cancer Res 2003; 9:5786-93.
23. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine). Cancer Res 1990; 50:4417-22.
24. Sebastiani V, Ricci F, Rubio-Viquiera B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12:2492-7.
25. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12:1794-803.
26. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10.
27. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33:S18-22.